Security Alert

Beware of fraudulent messages impersonating amana.

We have been made aware of fraudulent emails, messages, and job offers circulating online from individuals falsely claiming to represent amana.

These scams may promise investment opportunities, employment, or financial rewards while requesting personal information, payments, or account details.

Please note that the only official amana website is
www.amana.app

Please also be aware of the following fraudulent domains impersonating amana:

amanacapital961
amana.live
getamana.com
client.amana-trade.com
amanatrade.net
amana-capital.net
amaanahcapitall.com

Deposit $200 to get a $100 trading bonus.

Use the promo code AMANAWEB.

Sign up now.*T&Cs Apply.

Terms & Conditions

  1. Offer valid for new users signing up on amana.
  2. How to Qualify for $100 Trading Bonus:
    • Sign up via the website.
    • Complete onboarding by providing the required details.
    • Enter promo code AMANAWEB at the final step.
    • Deposit $100 or more before your first trade.
    • Make your first trade.
  3. Once all steps are completed, you’ll receive a $100 non-withdrawable trading bonus.
  4. Bonuses are credited during the first week of every month.
  5. The bonus can only be used for trading and cannot be withdrawn.
  6. The campaign is exclusive to selected amana customers.
  7. amana reserves the right to cancel bonuses in cases of suspected fraud.
ALLO icon

ALLO

1.18 USD

+0.86%

Today

+3.54%

1D

Market is closed

Sun

Closed

Mon

4:30 PM ~ 10:59 PM

Tue

4:30 PM ~ 10:59 PM

Wed

4:30 PM ~ 10:59 PM

Thu

4:30 PM ~ 10:59 PM

Fri

4:30 PM ~ 10:59 PM

Sat

Closed

Loading chart...
1D
5D
1M
3M
1Y
MAX

Information

Name

Allogene Therapeutics

Currency

USD

Market Cap

386.95M

Avg Daily Volume

5.99M

52 Week High

4.46 USD

52 Week Low

1.04 USD

Trading Hours

See hours

Business Summary

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Top News

Allogene

+8.49%

Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting

tradingview.com

1d ago

No Image

Allogene

+8.49%

Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data

tradingview.com

6d ago

No Image

Allogene

+8.49%

ALLO Q3'26 Earnings: revenue estimate is 2.50K USD

tradingview.com

1w ago

No Image

Show more

Frequently Asked Questions

What are healthcare stocks and why are they important to investors?

Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.


Are healthcare stocks less volatile?

Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.


What drives growth in healthcare investments?

Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.


What are the risks of investing in healthcare?

Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.